(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Exclusive-Head of Pemex's production arm to step down in coming days, sources say - 2The Main 20 Photography Instagram Records to Follow
- 3Find the Native Culinary Customs: Local Flavors
- 4Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- 5Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- NASA counts down for first crewed lunar mission in half a century
- The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- Giude to Best Web based Learning Stage
- FDA approves Wegovy pill for weight loss
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- Artemis II astronauts will see parts of the moon no human has before. Here’s how
- Rick Steves Recommends This German Town's Castle Hotel With Rhine River Views
- 7 Logically Demonstrated Techniques for Better Rest
- Smooth countdown continues for Artemis II moon mission
